synthesize

{
  "ranked_hypotheses": [
    {
      "title": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation as proximal driver in Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates",
      "description": "RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation should produce a measurable proximal phenotype before late disease pathology. The decisive test is time-resolved iPSC motor-neuron perturbations combining RNA stoichiometry, PTM mapping, live-cell condensate tracking, and cryo-electron tomography.",
      "target_gene": "FUS",
      "dimension_scores": {
        "evidence_strength": 0.62,
        "novelty": 0.72,
        "feasibility": 0.67,
        "therapeutic_potential": 0.64,
        "mechanistic_plausibility": 0.7,
        "druggability": 0.54,
        "safety_profile": 0.52,
        "competitive_landscape": 0.58,
        "data_availability": 0.66,
        "reproducibility": 0.61
      },
      "composite_score": 0.626,
      "evidence_for": [
        {
          "claim": "Comprehensive review of biomolecular condensate biophysics identified the liquid-to-solid transition in disease-associated RBPs as a major open question requiring in-cell structural approaches.",
          "doi": "10.1021/acs.chemrev.4c00138",
          "source": "Fundamental Aspects of Phase-Separated Biomolecular Condensates"
        }
      ],
      "evidence_against": [
        {
          "claim": "in-vitro condensate rules may not transfer cleanly to crowded, stressed patient neurons",
          "doi": "10.1021/acs.chemrev.4c00138",
          "source": "Fundamental Aspects of Phase-Separated Biomolecular Condensates"
        }
      ]
    },
    {
      "title": "Cell-state stratification is required to resolve Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates",
      "description": "The question is likely underpowered or misleading unless analyses preserve the key strata: FUS, TDP-43, RNA. Averaging across these strata could convert a causal subpopulation effect into a weak association.",
      "target_gene": "TDP-43",
      "dimension_scores": {
        "evidence_strength": 0.58,
        "novelty": 0.64,
        "feasibility": 0.73,
        "therapeutic_potential": 0.55,
        "mechanistic_plausibility": 0.65,
        "druggability": 0.45,
        "safety_profile": 0.62,
        "competitive_landscape": 0.56,
        "data_availability": 0.7,
        "reproducibility": 0.64
      },
      "composite_score": 0.612,
      "evidence_for": [
        {
          "claim": "The open question explicitly depends on cell-type, region, or molecular-state resolution.",
          "doi": "10.1021/acs.chemrev.4c00138"
        }
      ],
      "evidence_against": [
        {
          "claim": "Stratified effects may reflect sampling or annotation artifacts rather than mechanism.",
          "doi": "10.1021/acs.chemrev.4c00138"
        }
      ]
    },
    {
      "title": "Perturbation-first validation should precede therapeutic claims for Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates",
      "description": "The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.",
      "target_gene": "RNA",
      "dimension_scores": {
        "evidence_strength": 0.55,
        "novelty": 0.6,
        "feasibility": 0.76,
        "therapeutic_potential": 0.57,
        "mechanistic_plausibility": 0.63,
        "druggability": 0.48,
        "safety_profile": 0.6,
        "competitive_landscape": 0.55,
        "data_availability": 0.68,
        "reproducibility": 0.66
      },
      "composite_score": 0.608,
      "evidence_for": [
        {
          "claim": "The proposed priority experiment is concrete: time-resolved iPSC motor-neuron perturbations combining RNA stoichiometry, PTM mapping, live-cell condensate tracking, and cryo-electron tomography",
          "doi": "10.1021/acs.chemrev.4c00138"
        }
      ],
      "evidence_against": [
        {
          "claim": "Therapeutic tractability is not established by the current source evidence.",
          "doi": "10.1021/acs.chemrev.4c00138"
        }
      ]
    }
  ],
  "knowledge_edges": [
    {
      "source_id": "52661eaf-79f8-4647-8f48-3389f5af4d59",
      "source_type": "analysis",
      "target_id": "FUS",
      "target_type": "entity",
      "relation": "debate_reconstructs_evidence_for"
    },
    {
      "source_id": "52661eaf-79f8-4647-8f48-3389f5af4d59",
      "source_type": "analysis",
      "target_id": "TDP-43",
      "target_type": "entity",
      "relation": "debate_reconstructs_evidence_for"
    },
    {
      "source_id": "52661eaf-79f8-4647-8f48-3389f5af4d59",
      "source_type": "analysis",
      "target_id": "RNA",
      "target_type": "entity",
      "relation": "debate_reconstructs_evidence_for"
    }
  ],
  "synthesis_summary": "Consensus: Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates is a valid debate target because it is anchored to Fundamental Aspects of Phase-Separated Biomolecular Condensates and asks a falsifiable question about RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation. Dissent: the source evidence does not yet prove causality, and in-vitro condensate rules may not transfer cleanly to crowded, stressed patient neurons. The next step is time-resolved iPSC motor-neuron perturbations combining RNA stoichiometry, PTM mapping, live-cell condensate tracking, and cryo-electron tomography."
}